Immunologic Monitoring of Patients with Alveolar Soft Part Sarcoma Receiving a Long Translocation-Specific Peptide Vaccine with GM-CSF Adjuvant
We are developing a long amino acid peptide vaccine to be used with GM-CSF adjuvant to target the ASPL/TFE3 breakpoint translocation of alveolar soft part sarcoma (ASPS). We will address two specific aims: 1) Can CD8+ and CD4+ T-cell responses be generated to this vaccine by ASPS patients of different HLA haplotypes? 2) Can these general immune responses help determine HLA-specific immunogenic peptides for use in future trials? By using a long peptide sequence we can target patients of different HLA types as well as measure class I and class II responses to optimize future vaccines capable of destroying ASPS.